BioLineRx’s (BLRX) Hold Rating Reaffirmed at Jones Trading

BioLineRx (NASDAQ:BLRX)‘s stock had its “hold” rating restated by investment analysts at Jones Trading in a report issued on Wednesday,Benzinga reports.

Several other brokerages have also recently weighed in on BLRX. StockNews.com cut BioLineRx from a “hold” rating to a “sell” rating in a report on Tuesday, March 18th. HC Wainwright raised their target price on shares of BioLineRx from $9.00 to $26.00 and gave the stock a “buy” rating in a report on Monday.

BioLineRx Stock Performance

BioLineRx stock opened at $2.92 on Wednesday. The firm has a fifty day simple moving average of $3.50 and a two-hundred day simple moving average of $10.62. The company has a quick ratio of 1.37, a current ratio of 1.52 and a debt-to-equity ratio of 2.11. BioLineRx has a twelve month low of $2.80 and a twelve month high of $37.22. The company has a market capitalization of $9.72 million, a PE ratio of -0.33 and a beta of 1.39.

Hedge Funds Weigh In On BioLineRx

An institutional investor recently bought a new position in BioLineRx stock. Highbridge Capital Management LLC purchased a new stake in BioLineRx Ltd. (NASDAQ:BLRX) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 1,010,012 shares of the biotechnology company’s stock, valued at approximately $215,000. Highbridge Capital Management LLC owned approximately 50.50% of BioLineRx as of its most recent SEC filing. Institutional investors own 1.56% of the company’s stock.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.